Abstract:
BACKGROUND:First-line treatment with FOLFOXIRI plus bevacizumab (BEV) is highly effective and regarded as one of the standards-of-care for patients with metastatic colorectal cancer (mCRC), despite the high incidence of neutropenia and diarrhea as side effects. AXEPT, an Asian phase III study, showed that modified CAPIRI+BEV [capecitabine (CAP: 1600 mg/m2), irinotecan (IRI: 200 mg/m2), and BEV (7.5 mg/m2)] was non-inferior to FOLFIRI+BEV as a second-line therapy for mCRC patients and was associated with a lower incidence of hematologic toxicities. Thus, a reduced dose of the CAP and IRI regimen in combination with oxaliplatin (OX) and BEV (CAPOXIRI+BEV) may be more feasible than FOLFOXIRI+BEV, without compromising efficacy. METHODS:QUATTRO-II is an open-label, multicenter, randomized phase II study. In Step 1, the recommended doses of OX and IRI will be investigated as a safety lead-in. In Step 2, patients will be randomized to the recommended dose of either CAPOXIRI+BEV or FOLFOXIRI+BEV. Induction triplet chemotherapy plus BEV treatments will be administered for up to 4 months followed by fluoropyrimidine plus BEV maintenance. The primary endpoint is progression-free survival (PFS). The similarity in PFS between the two arms will be evaluated by observing whether the point estimate of hazard ratio (HR) for PFS falls between 0.80 and 1.25. Ensuring a 70% probability that the observed HR will be "0.8 < HR < 1.25" under the assumption of the true HR of 1.0, and 100 patients will be evaluated during the 3-year study period. Secondary endpoints include overall survival, overall response rate, safety, and patient reported outcome (PRO) (FACT/GOG-Ntx4). DISCUSSION:Considering the lower incidence of hematologic toxicities with modified CAPIRI+BEV than with FOLFIRI+BEV, CAPOXIRI+BEV may be a promising treatment option if sufficient efficacy and lower hematologic toxicities are indicated in this study. Additionally, a lower incidence of peripheral sensory neuropathy (PSN) reported following CAPEOX treatment compared to that after FOLFOX in ACHIEVE, an adjuvant phase III trial, suggest that CAPOXIRI+BEV can mitigate OX-induced PSN. TRIAL REGISTRATION:Clinicaltrials.gov NCT04097444 . Registered September 20, 2019, https://clinicaltrials.gov/ct2/show/study/NCT04097444 / Japan Registry of Clinical Trials jRCTs041190072. Registered October 9, 2019.
journal_name
BMC Cancerjournal_title
BMC cancerauthors
Miyo M,Kato T,Yoshino T,Yamanaka T,Bando H,Satake H,Yamazaki K,Taniguchi H,Oki E,Kotaka M,Oba K,Miyata Y,Muro K,Komatsu Y,Baba H,Tsuji Adoi
10.1186/s12885-020-07186-5subject
Has Abstractpub_date
2020-07-23 00:00:00pages
687issue
1issn
1471-2407pii
10.1186/s12885-020-07186-5journal_volume
20pub_type
杂志文章相关文献
BMC CANCER文献大全abstract:BACKGROUND:Patients with advanced or metastatic non-small cell lung cancer (NSCLC) can develop acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors (TKIs) erlotinib and gefitinib. Here, we report the successful treatment with alternating chemotherapy and TKIs of two cases of advanced NSCLC...
journal_title:BMC cancer
pub_type: 杂志文章
doi:10.1186/1471-2407-11-90
更新日期:2011-03-02 00:00:00
abstract:BACKGROUND:Metastatic progression due to development or enrichment of therapy-resistant tumor cells is eventually lethal. Molecular characterization of such chemotherapy resistant tumor cell clones may identify markers responsible for malignant progression and potential targets for new treatment. Here, in a case of sta...
journal_title:BMC cancer
pub_type: 杂志文章
doi:10.1186/1471-2407-11-455
更新日期:2011-10-20 00:00:00
abstract:BACKGROUND:Cancer stem cell (CSC) hypothesis has not been well demonstrated by the lack of the most convincing evidence concerning a single cell capable of giving rise to a tumor. The scarcity in quantity and improper approaches for isolation and purification of CSCs have become the major obstacles for great developmen...
journal_title:BMC cancer
pub_type: 杂志文章
doi:10.1186/1471-2407-8-135
更新日期:2008-05-14 00:00:00
abstract:BACKGROUND:There are strong indications for a causal association between areca-nut consumption and cancers. In Meghalaya, India, the variety of areca-nut is used as raw and unprocessed form whose chemical composition and pharmacological actions have been reported. Yet we know little on the initial pathway involved in a...
journal_title:BMC cancer
pub_type: 杂志文章
doi:10.1186/1471-2407-13-315
更新日期:2013-06-28 00:00:00
abstract:BACKGROUND:Ramucirumab (RAM) with weekly paclitaxel (wPTX) is a standard second-line therapy for advanced or recurrent gastric cancer. Nanoparticle albumin-bound paclitaxel (nab-PTX), an albumin-bound form of PTX, was developed to improve the therapeutic index of taxane treatment. However, the ABSOLUTE trial showed the...
journal_title:BMC cancer
pub_type: 杂志文章
doi:10.1186/s12885-020-07047-1
更新日期:2020-06-12 00:00:00
abstract:BACKGROUND:Breast metastasis from lung cancer has been reported, but not from SCLC that is transformed from lung adenocarcinoma during maintenance treatment with epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI). Transformation to small cell lung cancer(SCLC), although uncommonly seen, has been asso...
journal_title:BMC cancer
pub_type: 杂志文章
doi:10.1186/s12885-016-2623-4
更新日期:2016-08-03 00:00:00
abstract:BACKGROUND:We evaluated possible diagnostic and prognostic values of serum midkine in malignant pleural mesothelioma in comparison with those of serum mesothelin, a well-established diagnostic biomarker. METHODS:Serum mesothelin and midkine levels were determined with an enzyme-linked immunosorbent assay. We examined ...
journal_title:BMC cancer
pub_type: 杂志文章
doi:10.1186/s12885-017-3209-5
更新日期:2017-03-23 00:00:00
abstract:BACKGROUND:Clinical studies implying the sunitinib multi-kinase inhibitor have led to disappointing results for breast cancer care but mostly focused on HER2-negative subtypes. Preclinical researches involving this drug mostly concern Triple Negative Breast Cancer (TNBC) murine models. Here, we explored the therapeutic...
journal_title:BMC cancer
pub_type: 杂志文章
doi:10.1186/s12885-015-1540-2
更新日期:2015-07-22 00:00:00
abstract:BACKGROUND:Recurrent/metastatic squamous cell carcinoma of the head and neck (SCCHN) has a poor prognosis and the combination of cisplatin and cetuximab, with or without 5-fluorouracil, is the gold standard treatment in this stage. Thus, the concomitant use of novel compounds represents a critical strategy to improve t...
journal_title:BMC cancer
pub_type: 杂志文章
doi:10.1186/s12885-016-2957-y
更新日期:2016-11-25 00:00:00
abstract:BACKGROUND:Early life social environment may influence breast cancer through shaping risk factors operating in early life, adolescence and adulthood, or may be associated with breast cancer risk independent of known risk factors. We investigated the associations between early life socioeconomic status (SES) and mammogr...
journal_title:BMC cancer
pub_type: 杂志文章
doi:10.1186/s12885-016-3010-x
更新日期:2017-01-10 00:00:00
abstract:BACKGROUND:Papillary carcinomas that measure 1.0cm or less are diagnosed as papillary thyroid microcarcinomas (PTMs). The clinical significance and recommendations for management of these PTMs is still evolving. The objective of the study was to compare the characteristics of small (<5mm) to large (≥ 5mm) papillary thy...
journal_title:BMC cancer
pub_type: 杂志文章
doi:10.1186/s12885-017-3120-0
更新日期:2017-02-16 00:00:00
abstract:BACKGROUND:Treatment with recombinant human granulocyte-colony stimulating factor (G-CSF) is accepted standard for prevention of chemotherapy-induced neutropenia. RGB-02 (Gedeon Richter) is a proposed biosimilar to pegylated G-CSF (Neulasta®, Amgen) with sustained release properties. This is a randomized, comparative, ...
journal_title:BMC cancer
pub_type: 杂志文章,多中心研究,随机对照试验
doi:10.1186/s12885-019-5329-6
更新日期:2019-02-06 00:00:00
abstract::An amendment to this paper has been published and can be accessed via the original article. ...
journal_title:BMC cancer
pub_type: 已发布勘误
doi:10.1186/s12885-020-07245-x
更新日期:2020-09-01 00:00:00
abstract:BACKGROUND:The association between colorectal cancer (CRC) and smoking has not been consistent. Incomplete smoking history and association to a specific subset of CRC tumors have been proposed as explanations. The adenomatous polyposis coli (APC) gene has been reported to have a "gatekeeper" function in the colonic muc...
journal_title:BMC cancer
pub_type: 杂志文章
doi:10.1186/1471-2407-6-71
更新日期:2006-03-17 00:00:00
abstract:BACKGROUND:C3H mice have been frequently used in cancer studies as animal models of spontaneous liver tumors and chemically induced hepatocellular carcinoma (HCC). Epigenetic modifications, including DNA methylation, are among pivotal control mechanisms of gene expression leading to carcinogenesis. Although information...
journal_title:BMC cancer
pub_type: 杂志文章
doi:10.1186/s12885-018-4221-0
更新日期:2018-03-22 00:00:00
abstract:BACKGROUND:Choriocarcinoma is a gestational trophoblastic tumor which causes high mortality if left untreated. MicroRNAs (miRNAs) are small non protein-coding RNAs which inhibit target gene expression. The role of miRNAs in choriocarcinoma, however, is not well understood. In this study, we examined the effect of miR-3...
journal_title:BMC cancer
pub_type: 杂志文章
doi:10.1186/1471-2407-13-25
更新日期:2013-01-18 00:00:00
abstract:BACKGROUND:Most currently known breast cancer predisposition genes play a role in DNA repair by homologous recombination. Recent studies conducted on RAD51 paralogs, involved in the same DNA repair pathway, have identified rare germline mutations conferring breast and/or ovarian cancer predisposition in the RAD51C, RAD...
journal_title:BMC cancer
pub_type: 杂志文章
doi:10.1186/1471-2407-13-484
更新日期:2013-10-19 00:00:00
abstract:BACKGROUND:The purpose of this study was to investigate the impact of the Controlling Nutritional Status (CONUT) score on survival compared with the platelet to lymphocyte ratio (PLR), the neutrophil to lymphocyte ratio (NLR), and the Glasgow Prognostic Score (GPS) in patients with resectable thoracic esophageal squamo...
journal_title:BMC cancer
pub_type: 杂志文章
doi:10.1186/s12885-016-2696-0
更新日期:2016-09-06 00:00:00
abstract:BACKGROUND:No consensus treatment has been reached for hepatocellular carcinoma (HCC) with portal vein tumor thrombus (PVTT). Hepatic resection (HR) and transarterial chemoembolization (TACE) have been recommended as effective options, but which is better remains unclear. This meta-analysis is to compare the effectiven...
journal_title:BMC cancer
pub_type: 杂志文章,meta分析,评审
doi:10.1186/s12885-017-3895-z
更新日期:2017-12-28 00:00:00
abstract:BACKGROUND:Although socioeconomic status (SES) has been focused on as a key determinant of cancer stage at diagosis in western countries, there has been no systemic study on the relationship of SES and breast cancer stage at diagnosis in China. METHODS:The medical charts of 4,211 eligible breast cancer patients from 7...
journal_title:BMC cancer
pub_type: 杂志文章
doi:10.1186/1471-2407-12-122
更新日期:2012-03-29 00:00:00
abstract:BACKGROUND:It is well established that genetic and epigenetic alterations are common events in prostate cancer, which may lead to aberrant expression of critical genes. The importance of epigenetic mechanisms in prostate cancer carcinogenesis is increasingly evident. In this study, the focus will be on histone modifica...
journal_title:BMC cancer
pub_type: 杂志文章
doi:10.1186/1471-2407-14-994
更新日期:2014-12-23 00:00:00
abstract:BACKGROUND:Little information is available concerning how patient delay may be affected by mass disasters. The main objectives of the present study are to identify whether there was a post-disaster increase in the risk of experiencing patient delay among breast cancer patients in an area affected by the 2011 triple dis...
journal_title:BMC cancer
pub_type: 杂志文章
doi:10.1186/s12885-017-3412-4
更新日期:2017-06-19 00:00:00
abstract:BACKGROUND:In China, there are currently no approved therapies for the treatment of metastatic renal cell carcinoma (mRCC) following progression with vascular endothelial growth factor (VEGF)-targeted agents. In the phase 3 RECORD-1 trial, the mammalian target of rapamycin (mTOR) inhibitor everolimus afforded clinical ...
journal_title:BMC cancer
pub_type: 杂志文章,多中心研究
doi:10.1186/1471-2407-13-136
更新日期:2013-03-21 00:00:00
abstract:BACKGROUND:Presently available flow cytometric methods of bromodeoxyuridine (BrdUrd) labelling do not provide information on the cell cycle time (TC) and the growth fraction (GF). In this paper, we describe a novel and simple method to estimate TC and GF from flow cytometric analysis of a single tumour sample after Brd...
journal_title:BMC cancer
pub_type: 杂志文章
doi:10.1186/1471-2407-5-122
更新日期:2005-09-22 00:00:00
abstract::Following definitive chemoradiation for anal squamous cell carcinoma (ASCC), patients face a variety of chronic issues including: bowel dysfunction, accelerated bone loss, sexual dysfunction, and psychosocial distress. The increasing incidence of this disease, high cure rates, and significant long-term sequelae warran...
journal_title:BMC cancer
pub_type: 杂志文章,评审
doi:10.1186/s12885-019-6053-y
更新日期:2019-09-11 00:00:00
abstract:BACKGROUND:Gene-gene and gene-environment interactions involved in the metabolism of carcinogens may increase the risk of cancer. Our objective was to measure the interactions between common polymorphisms of P450 (CYP1A2, CYP1B1, CYP2E1), GSTM1 and T1, SULT1A1 and cigarette smoking in colorectal cancer (CRC). METHODS:...
journal_title:BMC cancer
pub_type: 杂志文章
doi:10.1186/1471-2407-7-115
更新日期:2007-06-30 00:00:00
abstract:BACKGROUND:In a phase I study of angiotensin-(1-7) [Ang-(1-7)], clinical benefit was associated with reduction in plasma placental growth factor (PlGF) concentrations. The current study examines Ang-(1-7) induced changes in biomarkers according to cancer type and investigates mechanisms of action engaged in vitro. MET...
journal_title:BMC cancer
pub_type: 杂志文章
doi:10.1186/1471-2407-12-404
更新日期:2012-09-11 00:00:00
abstract:BACKGROUND:Thymidylate synthase (TS) and Topoisomerase I (Topo I) are significant biomarkers in colorectal cancer (CRC). We aimed to study the expression of TS and Topo I in patients with resected CRC who received adjuvant chemotherapy and correlated it with clinical outcome. METHODS:All patients diagnosed with CRC be...
journal_title:BMC cancer
pub_type: 杂志文章
doi:10.1186/1471-2407-9-339
更新日期:2009-09-24 00:00:00
abstract:BACKGROUND:Population attributable risks (PARs) are useful tool to estimate the burden of risk factors in cancer incidence. Few studies estimated the PARs of oral cavity cancer to tobacco smoking alone, alcohol drinking alone and their joint consumption but none performed analysis stratified by subsite, gender or age. ...
journal_title:BMC cancer
pub_type: 杂志文章,多中心研究
doi:10.1186/s12885-015-1841-5
更新日期:2015-10-31 00:00:00
abstract:BACKGROUND:3,3'-diindolylmethane (DIM) is an acid-catalyzed dimer of idole-3-carbinol (I3C), a phytochemical found in cruciferous vegetables that include broccoli, Brussels sprouts and cabbage. DIM is an aryl hydrocarbon receptor (AhR) ligand and a potential anticancer agent, namely for the treatment of breast cancer. ...
journal_title:BMC cancer
pub_type: 杂志文章
doi:10.1186/1471-2407-14-524
更新日期:2014-07-21 00:00:00